PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Xultophy - Diabetes Mellitus

PAD Profile : Xultophy - Diabetes Mellitus

Keywords :
insulin degludec and 3.6 mg/mL liraglutide, GLP-1s, long acting insulin analogues
Brand Names Include :
Xultophy

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.

03 February 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN does not recommend the use of Xultophy (insulin degludec/liraglutide) and it will be considered BLACK on the traffic light system. See policy statement and evidence reviews for further information

Associated BNF Codes

06. Endocrine System
06.01.01. Insulin
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More